Yih Ming Hsiao, MD | |
71 N Main St, Belchertown, MA 01007-9503 | |
(413) 323-5945 | |
(413) 323-5068 |
Full Name | Yih Ming Hsiao |
---|---|
Gender | Male |
Speciality | General Practice |
Location | 71 N Main St, Belchertown, Massachusetts |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1760472864 | NPI | - | NPPES |
000000008405 | Other | BOSTON HEALTHNET | |
13202 | Other | HEALTH NEW ENGLAND | |
0111686 | Other | MA HEALTH | |
4208702 | Other | AETNA | |
731348 | Other | TUFTS | |
0111686 | Medicaid | MA | |
G02007 | Other | BCBS MA | |
1301526002 | Other | CIGNA | |
70973 | Other | HARVARD PILGRIM |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 46066 (Massachusetts) | Primary |
Mailing Address | Practice Location Address |
---|---|
Yih Ming Hsiao, MD 71 N Main St, Belchertown, MA 01007-9503 Ph: (413) 323-5945 | Yih Ming Hsiao, MD 71 N Main St, Belchertown, MA 01007-9503 Ph: (413) 323-5945 |
News Archive
Aetna, Cigna and Humana ranked highest nationally on criteria including speed of health claim payments and fewest claims denied, according to the 2009 PayerView Rankings, the Boston Globe reports.
A set of 87 genes one day may be used to routinely determine which patients can be successfully treated for advanced rectal cancer without undergoing a surgical procedure, researchers announced at the 2009 Clinical Congress of the American College of Surgeons.
Human embryonic stem (ES) cells and adult cells reprogrammed to an embryonic stem cell-like state-so-called induced pluripotent stem or iPS cells-exhibit very few differences in their gene expression signatures and are nearly indistinguishable in their chromatin state, according to Whitehead Institute researchers.The pluripotency of ES cells fueled excitement over their use in regenerative medicine. While ethical hurdles associated with the clinical application of human ES cells appeared to have been overcome with the development of methods to create iPS cells, some recent research has suggested that ES and iPS cells have substantial differences in which sets of genes they express.
Results from ZETA, a phase III study in patients with advanced medullary thyroid cancer (MTC), showed that treatment with the investigational drug vandetanib significantly extended Progression Free Survival (PFS), the primary endpoint of the study, by demonstrating a 54% reduction in the rate of progression compared to placebo.
› Verified 9 days ago